Antiarrhythmic drugs. Part 3: rate-control drugs
release_xmoe6atz7bfejbf7y6sk4s5xai
by
Michael Sampson
2019 Volume 14, Issue 11, p1-11
Abstract
Rate-control drugs are used to reduce the ventricular rate during atrial arrhythmias and are widely used in both primary and secondary care. In this final instalment of a three-part article series, we evaluate three commonly used rate-control agents: bisoprolol, diltiazem, and digoxin. Of these, bisoprolol has the widest range of indications as it is also used in the prevention of ventricular arrhythmias. It has the best safety profile of the three drugs owing to its combined renal and hepatic excretion. Diltiazem and digoxin have a narrower range of use and carry a greater risk of toxicity as a result of their reliance on either hepatic or renal elimination. These issues are explored alongside consideration of evidence base for use, dosing, and interactions. The focus is on information that supports safe prescribing and administration.
In application/xml+jats
format
Archived Content
There are no accessible files associated with this release. You could check other releases for this work for an accessible version.
Know of a fulltext copy of on the public web? Submit a URL and we will archive it
access all versions, variants, and formats of this works (eg, pre-prints)
Crossref Metadata (via API)
Worldcat
SHERPA/RoMEO (journal policies)
wikidata.org
CORE.ac.uk
Semantic Scholar
Google Scholar